Protocol Ledger

NCT03777657 · Phase III · COMPLETED

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Interventional Phase III clinical trial protocol NCT03777657 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-13 Enrollment: 997 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03777657
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)997 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03777657
Protocol FieldVerified Registry Value
NCT IdentifierNCT03777657
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment997 participants (ACTUAL)
Registered Start Date2018-12-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03777657
Hospital Research SiteLocationSite Profile
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
Ohio State University Comprehensive Cancer CenterColumbus, OHOpen Hospital Dossier ->
Fox Chase Cancer CenterPhiladelphia, PAOpen Hospital Dossier ->
Reading HospitalWest Reading, PAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI